0

Close
 
Upcoming Allied Market Research
2023
Relapsing-remitting Multiple Sclerosis Market

Relapsing-Remitting Multiple Sclerosis Market

by Treatment (Immunomodulating Drugs, NrF2 Activators, Interferons, Others), by Route of Administration (Oral, Intravenous) and by End User (Hospitals, Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Therapeutics
Report Code: A12601
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Relapsing-remitting Multiple Sclerosis Market

Request Now !

Relapsing-remitting multiple sclerosis (RRMS) is a kind of multiple sclerosis. It is the most common type of multiple sclerosis (MS), accounting for around 85% of source of diagnoses. Relapses of MS occur in people with RRMS with periods of remission occurring in between. MS is a chronic, progressive condition of the central nervous system (CNS) in which your immune system attacks myelin, the protective layer around nerve fibers. Damage of the myelin causes the nerves inflammation, which makes it difficult for your brain to connect with the rest of your body.

The specific causes of RRMS and other types of MS is currently unknown. A combination of genetic and environmental factors, such as smoking, vitamin D deficiency, and certain viral infections, may all play a role. Although there is no cure for MS,  but treatment can help manage symptoms, treat relapses, and slow down the progression of the condition. A variety of medications and therapies are available. For example, medications can help with symptoms like fatigue and muscle stiffness. A physiotherapist can assist with mobility difficulties or muscle weakness.

COVID-19 Impact Analysis

COVID-19 is an infectious disease that first emerged in late December in the Hubei province of the Wuhan city in China. The virus that causes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),  is highly infectious and, is transmitted from person to person. Since the outbreak in December 2019, The disease has spread to almost 213 countries across the globe with the World Health Organization to declare it a pandemic on March 11, 2020.

Coronavirus disease 2019 (COVID-19) has caused an economic crisis along with the healthcare crisis. The COVID-19 pandemic has stretched the global healthcare system, and  developed countries are anticipated to experience an economic recession as a result. The pandemic has had an adverse impact on the healthcare system, with revenue dropping by a 50% to 70% drop since March. Several small hospitals, clinics, and nursing homes have been forced to shut their operations Furthermore, social distancing and localized curfews have resulted in delayed elective surgical procedures. Moreover, visa cancellations have disrupted medical tourism which can negatively impact the growth of relapsing-remitting multiple sclerosis market.

During the spread of the pandemic, however, the testing scale has increased, allowing for data sharing and provides reliable lab results.

Top Impacting Factors

An increase in the geriatric population is driving the growth of the global relapsing-remitting multiple sclerosis market. According to a recent study, one in every six people in the world would be 65 and older by the end of 2050. The situation is more pronounced in Europe and North America where  one in every four people will be affected. Already in 2018 the population of this age group has surpassed that of children aged 5 and under. This Increase in geriatric population will need healthcare facilities, which is expected to enhance growth of the  relapsing-remitting multiple sclerosis market.

The cost of drugs remains a major challenge for the growth of the market due to increased government interventions and various treatment options for multiple sclerosis. However, patent expiry of major drugs is key restraint of the global MS drugs market. Furthermore, stringent regulatory constraints restrict the growth of the global MS drugs market.

Key Market Trends

Monoclonal antibodies are now being increasingly employed for the treatment of RRMS. Many clinical trials are focused on novel drugs using antibodies. There is an increase in the demand for immunosuppressive drugs for treating this condition..

F. Hoffman-La Roche Ltd., launched Ocrevus in 2017, and it soon became one of the blockbusters profits -making drug.

Key Benefits of the Report

  • This study presents the analytical depiction of the relapsing-remitting multiple sclerosis market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the relapsing-remitting multiple sclerosis market share.
  • The current market is quantitatively analyzed to highlight the growth scenario of the relapsing-remitting multiple sclerosis market..
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and the competition that will take shape in the coming years.

Questions Answered in the Adenovirus Diagnostic Testing Report

  • Who are the leading market players active in the relapsing-remitting multiple sclerosis market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the relapsing-remitting multiple sclerosis market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What are the future projections that would help in taking further strategic steps?
  • What are the impacts of COVID-19 in the industry?
  • What is relapsing-remitting multiple sclerosis?
  • What is the prediction of the relapsing-remitting multiple sclerosis market in the future?
  • What are the current and predicted trends?

 Relapsing-Remitting Multiple Sclerosis Market Report Highlights

Aspects Details
By Treatment
  • Immunomodulating Drugs
  • NrF2 Activators
  • Interferons
  • Others
By Route of Administration
  • Oral
  • Intravenous
By End User
  • Hospitals
  • Clinics
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players GlaxoSmithKline, Pfizer, Inc., Biogen, Novartis, Teva Pharmaceutical Industries Ltd., Bayer HealthCare, Acorda Therapeutics Inc., Sanofi, Merck and Co., Inc., Roche
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET, BY TREATMENT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Treatment

    • 4.2. Immunomodulating Drugs

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. NrF2 Activators

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Interferons

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Others

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET, BY ROUTE OF ADMINISTRATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Route Of Administration

    • 5.2. Oral

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Intravenous

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Clinics

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Others

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Treatment

      • 7.2.3. Market Size and Forecast, By Route Of Administration

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Relapsing-remitting Multiple Sclerosis Market

        • 7.2.6.1. Market Size and Forecast, By Treatment
        • 7.2.6.2. Market Size and Forecast, By Route Of Administration
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Relapsing-remitting Multiple Sclerosis Market

        • 7.2.7.1. Market Size and Forecast, By Treatment
        • 7.2.7.2. Market Size and Forecast, By Route Of Administration
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Relapsing-remitting Multiple Sclerosis Market

        • 7.2.8.1. Market Size and Forecast, By Treatment
        • 7.2.8.2. Market Size and Forecast, By Route Of Administration
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Treatment

      • 7.3.3. Market Size and Forecast, By Route Of Administration

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Relapsing-remitting Multiple Sclerosis Market

        • 7.3.6.1. Market Size and Forecast, By Treatment
        • 7.3.6.2. Market Size and Forecast, By Route Of Administration
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Relapsing-remitting Multiple Sclerosis Market

        • 7.3.7.1. Market Size and Forecast, By Treatment
        • 7.3.7.2. Market Size and Forecast, By Route Of Administration
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Relapsing-remitting Multiple Sclerosis Market

        • 7.3.8.1. Market Size and Forecast, By Treatment
        • 7.3.8.2. Market Size and Forecast, By Route Of Administration
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Relapsing-remitting Multiple Sclerosis Market

        • 7.3.9.1. Market Size and Forecast, By Treatment
        • 7.3.9.2. Market Size and Forecast, By Route Of Administration
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Relapsing-remitting Multiple Sclerosis Market

        • 7.3.10.1. Market Size and Forecast, By Treatment
        • 7.3.10.2. Market Size and Forecast, By Route Of Administration
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Relapsing-remitting Multiple Sclerosis Market

        • 7.3.11.1. Market Size and Forecast, By Treatment
        • 7.3.11.2. Market Size and Forecast, By Route Of Administration
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Relapsing-remitting Multiple Sclerosis Market

        • 7.3.12.1. Market Size and Forecast, By Treatment
        • 7.3.12.2. Market Size and Forecast, By Route Of Administration
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Treatment

      • 7.4.3. Market Size and Forecast, By Route Of Administration

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Relapsing-remitting Multiple Sclerosis Market

        • 7.4.6.1. Market Size and Forecast, By Treatment
        • 7.4.6.2. Market Size and Forecast, By Route Of Administration
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Relapsing-remitting Multiple Sclerosis Market

        • 7.4.7.1. Market Size and Forecast, By Treatment
        • 7.4.7.2. Market Size and Forecast, By Route Of Administration
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Relapsing-remitting Multiple Sclerosis Market

        • 7.4.8.1. Market Size and Forecast, By Treatment
        • 7.4.8.2. Market Size and Forecast, By Route Of Administration
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Relapsing-remitting Multiple Sclerosis Market

        • 7.4.9.1. Market Size and Forecast, By Treatment
        • 7.4.9.2. Market Size and Forecast, By Route Of Administration
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Relapsing-remitting Multiple Sclerosis Market

        • 7.4.10.1. Market Size and Forecast, By Treatment
        • 7.4.10.2. Market Size and Forecast, By Route Of Administration
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Relapsing-remitting Multiple Sclerosis Market

        • 7.4.11.1. Market Size and Forecast, By Treatment
        • 7.4.11.2. Market Size and Forecast, By Route Of Administration
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Relapsing-remitting Multiple Sclerosis Market

        • 7.4.12.1. Market Size and Forecast, By Treatment
        • 7.4.12.2. Market Size and Forecast, By Route Of Administration
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Relapsing-remitting Multiple Sclerosis Market

        • 7.4.13.1. Market Size and Forecast, By Treatment
        • 7.4.13.2. Market Size and Forecast, By Route Of Administration
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Relapsing-remitting Multiple Sclerosis Market

        • 7.4.14.1. Market Size and Forecast, By Treatment
        • 7.4.14.2. Market Size and Forecast, By Route Of Administration
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Treatment

      • 7.5.3. Market Size and Forecast, By Route Of Administration

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Relapsing-remitting Multiple Sclerosis Market

        • 7.5.6.1. Market Size and Forecast, By Treatment
        • 7.5.6.2. Market Size and Forecast, By Route Of Administration
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Relapsing-remitting Multiple Sclerosis Market

        • 7.5.7.1. Market Size and Forecast, By Treatment
        • 7.5.7.2. Market Size and Forecast, By Route Of Administration
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Relapsing-remitting Multiple Sclerosis Market

        • 7.5.8.1. Market Size and Forecast, By Treatment
        • 7.5.8.2. Market Size and Forecast, By Route Of Administration
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Relapsing-remitting Multiple Sclerosis Market

        • 7.5.9.1. Market Size and Forecast, By Treatment
        • 7.5.9.2. Market Size and Forecast, By Route Of Administration
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Relapsing-remitting Multiple Sclerosis Market

        • 7.5.10.1. Market Size and Forecast, By Treatment
        • 7.5.10.2. Market Size and Forecast, By Route Of Administration
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Relapsing-remitting Multiple Sclerosis Market

        • 7.5.11.1. Market Size and Forecast, By Treatment
        • 7.5.11.2. Market Size and Forecast, By Route Of Administration
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Biogen

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Novartis

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Roche

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Bayer HealthCare

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Pfizer, Inc.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Merck And Co., Inc.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Sanofi

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Teva Pharmaceutical Industries Ltd.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. GlaxoSmithKline

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Acorda Therapeutics Inc.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET FOR IMMUNOMODULATING DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET FOR NRF2 ACTIVATORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET FOR INTERFERONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET FOR INTRAVENOUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET FOR CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 18. U.S. RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 19. U.S. RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 20. U.S. RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 21. CANADA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 22. CANADA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 23. CANADA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 31. FRANCE RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 32. FRANCE RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 36. GERMANY RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. ITALY RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 38. ITALY RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 39. ITALY RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. SPAIN RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 41. SPAIN RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. UK RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 44. UK RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 45. UK RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. RUSSIA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 47. RUSSIA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 48. RUSSIA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 51. REST OF EUROPE RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 56. CHINA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 57. CHINA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 58. CHINA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. JAPAN RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 60. JAPAN RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 61. JAPAN RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. INDIA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 63. INDIA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 64. INDIA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. AUSTRALIA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 69. AUSTRALIA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 70. AUSTRALIA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 71. THAILAND RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 72. THAILAND RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 73. THAILAND RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. MALAYSIA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 75. MALAYSIA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 76. MALAYSIA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 77. INDONESIA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 78. INDONESIA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 79. INDONESIA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 80. REST OF ASIA PACIFIC RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 83. LAMEA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 84. LAMEA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 85. LAMEA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 86. LAMEA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 87. BRAZIL RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 88. BRAZIL RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 89. BRAZIL RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH AFRICA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 91. SOUTH AFRICA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 92. SOUTH AFRICA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 93. SAUDI ARABIA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 94. SAUDI ARABIA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 95. SAUDI ARABIA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 96. UAE RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 97. UAE RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 98. UAE RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 99. ARGENTINA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 100. ARGENTINA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 101. ARGENTINA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 102. REST OF LAMEA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 103. REST OF LAMEA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 104. REST OF LAMEA RELAPSING-REMITTING MULTIPLE SCLEROSIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 105. BIOGEN: KEY EXECUTIVES
  • TABLE 106. BIOGEN: COMPANY SNAPSHOT
  • TABLE 107. BIOGEN: OPERATING SEGMENTS
  • TABLE 108. BIOGEN: PRODUCT PORTFOLIO
  • TABLE 109. BIOGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. NOVARTIS: KEY EXECUTIVES
  • TABLE 111. NOVARTIS: COMPANY SNAPSHOT
  • TABLE 112. NOVARTIS: OPERATING SEGMENTS
  • TABLE 113. NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 114. NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. ROCHE: KEY EXECUTIVES
  • TABLE 116. ROCHE: COMPANY SNAPSHOT
  • TABLE 117. ROCHE: OPERATING SEGMENTS
  • TABLE 118. ROCHE: PRODUCT PORTFOLIO
  • TABLE 119. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. BAYER HEALTHCARE: KEY EXECUTIVES
  • TABLE 121. BAYER HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 122. BAYER HEALTHCARE: OPERATING SEGMENTS
  • TABLE 123. BAYER HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 124. BAYER HEALTHCARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 125. PFIZER, INC.: KEY EXECUTIVES
  • TABLE 126. PFIZER, INC.: COMPANY SNAPSHOT
  • TABLE 127. PFIZER, INC.: OPERATING SEGMENTS
  • TABLE 128. PFIZER, INC.: PRODUCT PORTFOLIO
  • TABLE 129. PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 130. MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 131. MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 132. MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 133. MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 134. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 135. SANOFI: KEY EXECUTIVES
  • TABLE 136. SANOFI: COMPANY SNAPSHOT
  • TABLE 137. SANOFI: OPERATING SEGMENTS
  • TABLE 138. SANOFI: PRODUCT PORTFOLIO
  • TABLE 139. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 140. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 141. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 142. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 143. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 144. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. GLAXOSMITHKLINE: KEY EXECUTIVES
  • TABLE 146. GLAXOSMITHKLINE: COMPANY SNAPSHOT
  • TABLE 147. GLAXOSMITHKLINE: OPERATING SEGMENTS
  • TABLE 148. GLAXOSMITHKLINE: PRODUCT PORTFOLIO
  • TABLE 149. GLAXOSMITHKLINE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. ACORDA THERAPEUTICS INC.: KEY EXECUTIVES
  • TABLE 151. ACORDA THERAPEUTICS INC.: COMPANY SNAPSHOT
  • TABLE 152. ACORDA THERAPEUTICS INC.: OPERATING SEGMENTS
  • TABLE 153. ACORDA THERAPEUTICS INC.: PRODUCT PORTFOLIO
  • TABLE 154. ACORDA THERAPEUTICS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET
  • FIGURE 3. SEGMENTATION RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALRELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET
  • FIGURE 11. RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET SEGMENTATION, BY BY TREATMENT
  • FIGURE 12. RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET FOR IMMUNOMODULATING DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET FOR NRF2 ACTIVATORS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET FOR INTERFERONS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET SEGMENTATION, BY BY ROUTE OF ADMINISTRATION
  • FIGURE 17. RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET FOR ORAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET FOR INTRAVENOUS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 20. RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET FOR CLINICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 24. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 25. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 26. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 27. COMPETITIVE DASHBOARD
  • FIGURE 28. COMPETITIVE HEATMAP: RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET
  • FIGURE 29. Top player positioning, 2022
  • FIGURE 30. BIOGEN: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 31. BIOGEN: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 32. BIOGEN: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 33. NOVARTIS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. NOVARTIS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. NOVARTIS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. ROCHE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. ROCHE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. ROCHE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. BAYER HEALTHCARE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. BAYER HEALTHCARE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. BAYER HEALTHCARE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. PFIZER, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. PFIZER, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. MERCK AND CO., INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. SANOFI: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. SANOFI: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. SANOFI: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. GLAXOSMITHKLINE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. GLAXOSMITHKLINE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. GLAXOSMITHKLINE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. ACORDA THERAPEUTICS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. ACORDA THERAPEUTICS INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. ACORDA THERAPEUTICS INC.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Relapsing-remitting Multiple Sclerosis Market

Start reading.
This Report and over 66,965+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers